The Relationship between Health Insurance and Pharmaceutical Innovation: An Empirical Study Based on Meta-Analysis

被引:1
作者
Fan, Chenchen [1 ]
Song, Xiaoting [1 ]
Li, Chunyan [1 ]
机构
[1] Tongji Univ, Shanghai Int Coll Intellectual Property, Shanghai 200092, Peoples R China
关键词
health insurance; pharmaceutical innovation; meta-analysis; effect size; MEDICARE PART-D; MARKET-SIZE; COVERAGE; PRICE; LINK;
D O I
10.3390/healthcare11222916
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The growing research interest in the relationship between health insurance and pharmaceutical innovation is driven by their significant impact on healthcare optimization and pharmaceutical development. The existing literature, however, lacks consensus on this relationship and provides no evidence of the magnitude of a correlation. In this context, this study employs meta-analysis to explore the extent to which health insurance affects pharmaceutical innovation. It analyzes 202 observations from 14 independent research samples, using the regression coefficient of health insurance on pharmaceutical innovation as the effect size. The results reveal that there is a strong positive correlation between health insurance and pharmaceutical innovation (r = 0.367, 95% CI = [0.294, 0.436]). Public health insurance exhibits a stronger promoting effect on pharmaceutical innovation than commercial health insurance. The relationship between health insurance and pharmaceutical innovation is moderated by the country of sample origin, data range, journal type, journal impact factor, type of health insurance, and research perspective. Our research findings further elucidate the relationship mechanism between health insurance and pharmaceutical innovation, providing a valuable reference for future explorations in pharmaceutical fields.
引用
收藏
页数:18
相关论文
共 61 条
  • [1] Market size in innovation: Theory and evidence from the pharmaceutical industry
    Acemoglu, D
    Linn, J
    [J]. QUARTERLY JOURNAL OF ECONOMICS, 2004, 119 (03) : 1049 - 1090
  • [2] Did medicare induce pharmaceutical innovation?
    Acemoglu, Daron
    Cutler, David
    Finkelstein, Amy
    Linn, Joshua
    [J]. AMERICAN ECONOMIC REVIEW, 2006, 96 (02) : 103 - 107
  • [3] Association between Prescribers' Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability
    Adzrago, David
    Di Paola, Angela
    Zhu, Jialing
    Betancur, Alejandro
    Wilkerson, J. Michael
    [J]. HEALTHCARE, 2022, 10 (09)
  • [4] Insurance Design and Pharmaceutical Innovation
    Agha, Leila
    Kim, Soomi
    Li, Danielle
    [J]. AMERICAN ECONOMIC REVIEW-INSIGHTS, 2022, 4 (02) : 191 - 208
  • [5] Defining rewardable innovation in drug therapy
    Aronson, Jeffrey K.
    Ferner, Robin E.
    Hughes, Dyfrig A.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (04) : 253 - 254
  • [6] Autor D., 2016, FOREIGN COMPETITION, DOI [10.3386/w22879, DOI 10.3386/W22879]
  • [7] Bagley Nicholas, 2015, Correcting Signals for Innovation in Health Care
  • [8] Baik SH, 2012, J MENT HEALTH POLICY, V15, P105
  • [9] Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion
    Bennette, Caroline Savage
    Basu, Anirban
    Ramsey, Scott D.
    Helms, Zachary
    Bach, Peter B.
    [J]. AMERICAN JOURNAL OF HEALTH ECONOMICS, 2019, 5 (03) : 360 - 375
  • [10] Blume-Kohout M.E., 2008, The Impact of Medicare Part D on Pharmaceutical RD